Trillium Therapeutics proposes offering of series II convertible first preferred shares

By Abigail W. Adams

Portland, Me., Jan. 22 – Trillium Therapeutics Inc. has proposed an offering of series II convertible first preferred shares, according to a company news release.

Cowen is bookrunning manager for the registered offering, which carries a greenshoe equal to 15% of the offering size.

The convertible first preferred shares are pricing concurrently with a public offering and are being offered to investors whose purchase of common shares would result in a beneficial ownership of more than 4.99% of the outstanding common shares.

Proceeds will be used for the clinical development of a product in the company’s pipeline, for working capital and for general corporate purposes.

Trillium is a Cambridge, Mass.-based immune-oncology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.